ABITEC FEATURE ARTICLE IN DRUG DEVELOPMENT & DELIVERY
The US Food and Drug Administration (FDA) recently issued guidance intended to curtail the use of medically important antibiotics in agricultural applications. In the wake of these recommendations, the veterinary medicine community has mobilized to define and commercialize effective alternative pathogen controls. In this article, we draw attention to the scope of the challenge by highlighting some of the most significant, pathogen-borne diseases relevant to food-producing animals. We also review the antimicrobial properties intrinsic to midchain triglyceride lipolysis products, and present the question: What is the untapped potential of these safe-for-consumption, environmentally benign, and mechanistically privileged antimicrobial natural products?
About the Author:
Dr. Littich is responsible for the development of solution-driven lipid excipient technology and applications. Professionally, he draws on experience within a VC-backed biotechnology start-up, having led new product development in an organization commercializing Nobel Prize-winning catalyst technology to transform natural triglycerides into fine and specialty chemicals. He is a classically trained synthetic organic chemist with a foundation in the de novo synthesis of medicinally relevant, complex natural products. He earned his BA in Chemistry from Ferris State University, and his PhD in Synthetic Organic Chemistry from the University of Texas at Austin.
For further information, please contact:
Amanda Coulter, Manager: Marketing Research and Communications
614-429-6453 | [email protected]